Rockwell Medical, Inc.
RMTI- 1D
- +1.6%
Rockwell Medical, Inc. in brief
Rockwell Medical, Inc. is a listed company in the Pharmaceutical industry, based in Wixom, Michigan, USA. It was founded in 1996. Its market value was $32 M on 16 October 2026, which makes it the 22,794th largest listed company in the world and the 4,019th largest in the USA on this site. In the year to December 2025 it had sales of $69 M and a net loss of $5 M. Mark Strobeck is its chief executive. Its largest product and service lines by sales in 2025 were Concentrate Products Sales (100%) and License Fees (under 1%). By market, the largest shares of its 2025 sales came from USA (87%). Its shares trade under the symbol RMTI (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Rockwell Medical, Inc.
Rockwell Medical Inc. is a publicly traded pharmaceutical company based in Wixom, Michigan and founded in 1996 that focuses on development and commercialization of treatments against diseases such as end-stage renal disease (ESRD) and chronic kidney disease (CKD).
The company's primary customers are dialysis providers.
From Wikipedia: read the full article · text available under CC BY-SA 4.0
Rockwell Medical, Inc. timeline
- 1995
- 🏁· approximateFounded
- 1997
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 1998
- 🔔· approximateInitial public offering on Nasdaq as RMTI
- 2012
- ✎Renamed Rockwell Medical, Inc.Formerly Rockwell Medical Technologies Inc.
- 2024
- 💰Record revenue of $101 millionFY2024, the highest of the 8 years on record.
Events of Rockwell Medical, Inc. from Wikidata, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,436 (Jan 2020) · #3,735 (Jan 2021) · #5,048 (Jan 2022) · #5,529 (Dec 2022) · #4,213 (Jul 2023) · #4,068 (Jan 2024) · #2,225 (Mar 2026) · #3,878 (Aug 2026) · #4,008 (Oct 2026) · #4,022 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 0.4×
- Price / book
- 0.9×
- Free cash flow yield
- -3.7%
- Net margin (TTM)
- -7.8%
- Operating margin
- -6.8%
- Return on equity
- -15.3%
- Liabilities / assets
- 35.3%
- Net debt
- $-2M
- Revenue growth
- -31.8%
- R&D / revenue
- 0.0%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $69M | -31.8% | $-5M | $-5M | -7.7% |
| Dec 2024 | $101M | +21.4% | $1M | $-0M | -0.5% |
| Dec 2023 | $84M | +14.8% | $-7M | $-8M | -10.1% |
| Dec 2022 | $73M | +17.6% | $-17M | $-19M | -25.7% |
| Dec 2021 | $62M | -0.4% | $-30M | $-33M | -52.8% |
| Dec 2020 | $62M | +1.5% | $-28M | $-31M | -49.7% |
| Dec 2019 | $61M | -3.3% | $-35M | $-34M | -55.7% |
| Dec 2018 | $63M | — | $-32M | $-32M | -50.7% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-1M | $1M | $-1M | $-0.15 | — |
| Dec 2024 | $4M | $1M | $3M | $-0.03 | — |
| Dec 2023 | $-9M | $0M | $-10M | $-0.37 | — |
| Dec 2022 | $-17M | — | — | $-1.31 | — |
| Dec 2021 | $-34M | — | — | $-3.83 | — |
| Dec 2020 | $-30M | — | — | $-0.41 | — |
| Dec 2019 | $-27M | — | — | $-0.56 | — |
| Dec 2018 | $-20M | — | — | $-0.61 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $19M (+20.0% on a year earlier), net income $-2M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Nov 12, 20268-KCurrent reportResults of operations
- Nov 3, 20268-KCurrent reportMaterial agreement · Unregistered share sale · Regulation FD disclosure
- Aug 13, 20268-KCurrent reportRegulation FD disclosure
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Aug 13, 20268-KCurrent reportResults of operations
- Jul 20, 20268-KCurrent reportOther events
- Jun 29, 20268-KCurrent reportBylaws amended
- Jun 15, 20268-KCurrent reportShareholder vote
- May 8, 20268-KCurrent reportListing notice
- May 7, 20268-KCurrent reportRegulation FD disclosure
- May 7, 202610-QQuarterly report · period to Mar 2026
Official filings of Rockwell Medical, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $69 M
- Operating income
- $-5 M
- Net income
- $-5 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $57 M
- Total liabilities
- $20 M
- Total equity
- $37 M
As of December-2025
Top 27 institutional investors in Rockwell Medical, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 120,407 | New | 2.99% | $1 M | Nov 13, 2026 |
| 2 | Geode Capital Management, LLC | 39,703 | New | 0.99% | $0 M | Nov 6, 2026 |
| 3 | Renaissance Technologies LLC | 35,864 | New | 0.89% | $0 M | Nov 12, 2026 |
| 4 | Vanguard Fiduciary Trust Co | 23,266 | New | 0.58% | $0 M | Nov 13, 2026 |
| 5 | Wealthspire Advisors, LLC | 15,183 | New | 0.38% | $0 M | Nov 13, 2026 |
| 6 | BlackRock, Inc. | 14,173 | New | 0.35% | $0 M | Nov 13, 2026 |
| 7 | Jane Street Group, LLC | 11,417 | New | 0.28% | $0 M | Nov 12, 2026 |
| 8 | Gsa Capital Partners LLP | 10,568 | New | 0.26% | $0 M | Nov 16, 2026 |
| 9 | State Street Corp | 10,089 | New | 0.25% | $0 M | Nov 12, 2026 |
| 10 | UBS Group AG | 10,009 | New | 0.25% | $0 M | Nov 10, 2026 |
| 11 | Harbour Investments, Inc. | 1,749 | -20,116 (-92.00%) | 0.04% | $0 M | Nov 9, 2026 |
| 12 | Vanguard Global Advisers, LLC | 1,057 | New | 0.03% | $0 M | Nov 13, 2026 |
| 13 | Wells Fargo & Company/mn | 998 | New | 0.02% | $0 M | Nov 16, 2026 |
| 14 | Pinnacle Financial Group, Inc. | 700 | — | 0.02% | $0 M | Nov 16, 2026 |
| 15 | Morgan Stanley | 367 | New | 0.01% | $0 M | Nov 13, 2026 |
| 16 | Nuveen, LLC | 74 | New | 0.00% | $0 M | Nov 10, 2026 |
| 17 | IFG Advisory, LLC | 67 | New | 0.00% | $0 M | Nov 9, 2026 |
| 18 | Tower Research Capital LLC (TRC) | 66 | New | 0.00% | $0 M | Nov 16, 2026 |
| 19 | Kovack Advisors, Inc. | 58 | New | 0.00% | $0 M | Nov 13, 2026 |
| 20 | William Mack & Associates, Inc. | 30 | New | 0.00% | $0 M | Oct 27, 2026 |
| 21 | Osaic Holdings, Inc. | 27 | New | 0.00% | $0 M | Nov 12, 2026 |
| 22 | Jones Financial Companies Lllp | 25 | New | 0.00% | $0 M | Nov 13, 2026 |
| 23 | Fifth Third Bancorp | 16 | New | 0.00% | $0 M | Nov 5, 2026 |
| 24 | Compass Financial Management LLC | 12 | 0 (0.00%) | 0.00% | $0 M | Oct 30, 2026 |
| 25 | SBI Securities Co., Ltd. | 5 | -62 (-92.54%) | 0.00% | $0 M | Oct 22, 2026 |
Show all 27: investors 26 to 27
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Jpmorgan Chase & Co | 3 | New | 0.00% | $0 M | Nov 12, 2026 |
| 27 | Farther Finance Advisors, LLC | 3 | New | 0.00% | $0 M | Oct 8, 2026 |
Mutual funds holding Rockwell Medical, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 844,926 | $0 M | — | <0.01% | +6.1% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 359,156 | $0 M | — | <0.01% | −0.4% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 218,753 | $0 M | — | <0.01% | +16% | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 52,325 | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 49,481 | $0 M | — | <0.01% | +3.2% | May 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 25,806 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 17,380 | $0 M | — | <0.01% | no change | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 7 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Rockwell Medical, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Mark StrobeckPresident and CEO, Director | Sell10b5-1 plan | -1,000 | $8.420 | $8 K | 61,349 | Form 4 |
| filed | Joseph H. DawsonDirector | Grant or award | +9,633 | — | — | 12,133 | Form 4 |
| filed | Jesse NeriSVP and CFO | Grant or award | +15,000 | — | — | 27,239 | Form 4 |
| filed | Mark StrobeckPresident and CEO, Director | Grant or award | +30,000 | — | — | 62,349 | Form 4 |
| filed | Timothy CholeSVP and CCO | Grant or award | +15,000 | — | — | 27,285 | Form 4 |
| filed | Megan C. TimminsEVP, CLO & Secretary | Grant or award | +15,000 | — | — | 31,240 | Form 4 |
| filed | Robert S. RadieDirector | Grant or award | +9,633 | — | — | 23,985 | Form 4 |
| filed | Joan LauDirector | Grant or award | +9,633 | — | — | 20,944 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Rockwell Medical, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-10 reverse split ; 1-for-10 reverse split
Trading halts
- 2026-06-30 23:50 UTC, code T3, resumed 13:00 UTC
Fails to deliver
- : 29 shares at $7.98
- : 1,306 shares at $7.85
- : 330 shares at $8.55
- : 799 shares at $8.63
- : 199 shares at $8.37
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Rockwell Medical, Inc. scorecard#
Passes 7 of the 22 checks that could be worked out: strongest in financial health (3 of 5), weakest in growth (1 of 6). Fiscal year 2025; market cap of Oct 16, 2026.
Valuation2 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median0.9×Price to book 0.9× against Pharmaceutical's median of 3.2×.
- ✓Price to sales below its peers' median0.4×Price to sales 0.4× against Pharmaceutical's median of 3.5×.
- ✗Free cash flow yield above 5%-3.7%Free cash flow is -3.7% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 6
- ✗Revenue grew in the newest year-31.8%Revenue down 31.8% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years-1.6%-1.6% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median-1.6%-1.6% a year against Pharmaceutical's median of 2.5% (65 companies).
- ✗Earnings per share grew in the newest year-0.15 vs -0.03Diluted EPS -0.15 in fiscal 2025 against -0.03 the year before (report's currency).
- ✓Net income higher than five years earlier-$5 M-$5 M in fiscal 2025 against -$31 M in 2020.
- ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2025.
Profitability1 of 5
- ✗Profitable in the newest year-$5 MNet income -$5 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-6.8%-6.8% against Pharmaceutical's median of 1.8% (74 companies).
- ✗Return on equity above 15%-15.3%-15.3% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-6.8%-6.8% in fiscal 2025 against -23.0% in 2022.
Financial health3 of 5
- ✓Short-term assets cover short-term liabilities4.0×Current ratio 3.98 at the end of fiscal 2025.
- ✓Debt below equity0.2×Debt to equity 0.24 at the end of fiscal 2025.
- ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $2 M at the end of fiscal 2025.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-7.38Z-score -7.38 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year15.8%Diluted shares up 15.8% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Rockwell Medical, Inc.'s statements, beside the median of Pharmaceutical.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -6.8% | 1.8% | |
| Net margin | -7.7% | -1.5% | |
| Return on equity | -15.3% | -0.9% | |
| Revenue growth, 3 years a year | -1.7% | 2.5% | |
| Revenue growth | -31.8% | 7.3% | |
| Debt to equity | 0.24× | 0.66× |
3of 9on the Piotroski tests of financial strength
- Revenue fell 31.8% against the year before.
- Net loss of $5 million, the 17th loss-making year in a row.
- Free cash flow was negative: -$1 million.
- The share count rose 15.8% in the year.
Rockwell Medical, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 69−31.8%100% | 101+21.4%100% | 84+14.8%100% | 73+17.6%100% | 62−0.4%100% | 62+1.5%100% | 61r61−3.3%100% | 63+10.6%100% | 57+7.5%100% | 53—100% | |
| Cost of revenue | 58−31.5%83.1% | 84+12.1%82.8% | 75+9.0%89.6% | 69+6.8%94.4% | 64+8.2%104% | 59+1.7%95.6% | 58r58−10.0%95.4% | 65+21.2%102% | 54+15.2%93.5% | 47—87.3% | |
| Gross profit | 12−33.1%16.9% | 17+101%17.2% | 8.7+113%10.4% | 4.1—5.6% | −2.4−189%−3.9% | 2.7−4.0%4.4% | 2.8r2.8—4.6% | −1.6−143%−2.5% | 3.7−45.2%6.5% | 6.8—12.7% | |
| Research and development | 0−100%0.0% | 0.0−98.3%0.0% | 1.1−64.5%1.3% | 3.1−54.4%4.3% | 6.8−3.6%11.0% | 7.1+3.0%11.4% | 6.9r6.9+22.0%11.2% | 5.6−10.7%8.9% | 6.3+8.2%11.0% | 5.8—11.0% | |
| Selling, general and administrative | — | — | — | — | — | — | — | 23−0.9%36.4% | 23+10.3%40.7% | 21—39.6% | |
| Selling and marketing | 2.4−14.4%3.4% | 2.7+29.4%2.7% | 2.1+1.5%2.5% | 2.1−63.5%2.9% | 5.7−27.2%9.3% | 7.9−13.0%12.7% | 9.1r9.1+801%14.8% | 1.0—1.6% | — | — | |
| General and administrative | 14−0.5%20.3% | 14+16.2%13.9% | 12−22.4%14.5% | 16+1.9%21.5% | 15−5.2%24.8% | 16−22.9%26.0% | 21r21−4.9%34.3% | 22—34.8% | — | — | |
| Operating income | −4.7−872%−6.8% | 0.6—0.6% | −6.7—−8.0% | −17—−23.0% | −30—−49.0% | −28—−45.7% | −35r−35—−56.3% | −32—−51.2% | −26—−45.2% | −20—−37.9% | |
| Interest and finance income | — | — | 0.2+539%0.3% | 0.0+50.0%0.0% | 0.0−90.8%0.0% | 0.2−39.3%0.4% | 0.4—0.6% | — | — | 0.8—1.5% | |
| Interest expense and finance costs | 1.1−10.4%1.6% | 1.3−45.5%1.2% | 2.3+18.9%2.8% | 1.9−18.0%2.7% | 2.4+25.6%3.8% | 1.9+7416%3.0% | 0.0—0.0% | — | — | — | |
| Net interest income | — | — | — | — | — | — | 0.4−31.5%0.6% | 0.5r0.5−32.2%0.8% | 0.8—1.4% | — | |
| Other non-operating income (expense) | −0.6—−0.9% | −1.1—−1.1% | −1.8—−2.1% | −1.9—−2.6% | −2.3—−3.8% | −2.5−722%−4.0% | 0.4r0.4+26.7%0.6% | 0.3+19074%0.5% | 0.0—0.0% | — | |
| Income before tax | −5.3—−7.7% | −0.5—−0.5% | −8.4—−10.1% | — | — | — | — | — | −26—−45.2% | −19—−36.4% | |
| Income tax | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0−100%0.0% | 0.4—0.8% | |
| Net income attributable to shareholders | −5.3—−7.7% | −0.5—−0.5% | −8.4—−10.1% | −19—−25.7% | −33—−52.8% | −31—−49.7% | −34r−34—−55.7% | −32—−50.7% | −26—−45.2% | −20—−37.2% | |
| Earnings per share, basic | -0.15—— | -0.03—— | -0.37—— | -1.31r-1.89—— | -3.83r-0.35—— | -0.41—— | -0.56—— | -0.61—— | -0.51—— | -0.39—— | |
| Earnings per share, diluted | -0.15—— | -0.03—— | -0.37—— | -1.31r-1.89—— | -3.83r-0.35—— | -0.41—— | -0.56—— | -0.61—— | -0.51—— | -0.39—— | |
| Shares, weighted average (basic) | 36+15.8%— | 31+33.2%— | 23+63.0%— | 14r9.9+67.8%— | 8.5r94−88.7%— | 76—— | — | — | 51+0.8%— | 51—— | |
| Shares, weighted average (diluted) | 36+15.8%— | 31+33.2%— | 23+63.0%— | 14r9.9+67.8%— | 8.5r94−88.7%— | 76+24.1%— | 61+15.3%— | 53+3.4%— | 51+0.8%— | 51—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 11−31.6%18.7% | 16+74.4%26.5% | 9.0−11.1%17.2% | 10−23.9%21.7% | 13−72.7%27.3% | 49+313%62.6% | 12r12−48.1%26.6% | 23+170%43.2% | 8.4−51.1%14.3% | 17—20.7% | |
| Short-term investments | 14+141%25.0% | 5.9+204%10.0% | 2.0−82.9%3.7% | 11+24.4%24.4% | 9.2−8.4%18.9% | 10.0−29.8%12.9% | 14r14+31.7%32.2% | 11—20.6% | — | — | |
| Receivables | 8.1−1.8%14.2% | 8.3−23.9%14.0% | 11+74.2%20.9% | 6.3+5.9%13.4% | 5.9+41.8%12.2% | 4.2−0.8%5.4% | 4.2r4.2−39.8%9.5% | 7.0+9.8%13.3% | 6.4−0.6%10.8% | 6.4—7.7% | |
| Inventory | 3.4−40.7%6.0% | 5.8−1.6%9.8% | 5.9+1.0%11.3% | 5.8+42.6%12.5% | 4.1+4.2%8.4% | 3.9+7.3%5.0% | 3.6r3.6−9.7%8.2% | 4.0−47.1%7.7% | 7.6−37.1%13.0% | 12—14.6% | |
| Other current assets | 1.6+17.7%2.8% | 1.4+27.8%2.3% | 1.1−39.1%2.0% | 1.7−39.0%3.7% | 2.9+5.7%5.9% | 2.7−9.2%3.5% | 3.0r3.0+56.5%6.7% | 1.9+6.9%3.6% | 1.8−12.5%3.0% | 2.0—2.4% | |
| Current assets | 38+3.1%66.8% | 37+28.7%62.5% | 29−18.5%55.1% | 35+0.1%75.7% | 35−49.2%72.6% | 69+88.4%89.4% | 37r37−21.3%83.2% | 47−4.1%89.1% | 49−37.8%83.1% | 79—94.4% | |
| Property, plant and equipment | 4.6−20.0%8.1% | 5.8−9.6%9.8% | 6.4+192%12.3% | 2.2−11.7%4.7% | 2.5−5.9%5.1% | 2.6+8.6%3.4% | 2.4r2.4−7.8%5.5% | 2.6+3.5%5.0% | 2.5+83.2%4.3% | 1.4—1.7% | |
| Right-of-use (leased) assets | 2.6−20.1%4.5% | 3.2+18.5%5.4% | 2.7−31.2%5.2% | 3.9−48.8%8.5% | 7.7+166%15.9% | 2.9r2.9−9.7%3.7% | 3.2r3.2—7.3% | — | — | — | |
| Goodwill | 0.90.0%1.6% | 0.90.0%1.6% | 0.90.0%1.8% | 0.90.0%2.0% | 0.90.0%1.9% | 0.90.0%1.2% | 0.9r0.9+0.0%2.1% | 0.90.0%1.8% | 0.90.0%1.6% | 0.9—1.1% | |
| Other intangible assets | 9.7−5.4%16.9% | 10−5.1%17.2% | 11—20.6% | 0—0.0% | — | — | — | — | 0.0−8.1%0.0% | 0.0—0.0% | |
| Total assets | 57−3.5%100% | 59+13.5%100% | 52+11.9%100% | 47−4.0%100% | 49−37.5%100% | 78+75.4%100% | 44r44−15.7%100% | 53−10.6%100% | 59−29.3%100% | 83—100% | |
| Accounts payable | 2.0−30.3%3.5% | 2.9−36.5%4.8% | 4.5+11.4%8.7% | 4.1+8.4%8.7% | 3.7−10.0%7.7% | 4.2+37.7%5.3% | 3.0r3.0−32.8%6.8% | 4.5+6.4%8.5% | 4.2−27.9%7.2% | 5.9—7.0% | |
| Debt due within a year | 0—0.0% | — | 0−100%0.0% | 1.6−77.9%3.5% | 7.4—15.2% | 0—0.0% | — | — | — | — | |
| Current liabilities | 9.6−32.0%16.8% | 14−15.3%23.8% | 17−6.0%31.9% | 18−15.6%37.9% | 21+63.9%43.2% | 13+3.4%16.5% | 12r12−6.3%27.9% | 13+44.4%25.1% | 9.1−9.9%15.6% | 10—12.2% | |
| Long-term debt | 8.8+4.2%15.4% | 8.5+2.2%14.3% | 8.3+9.8%15.9% | 7.6−42.7%16.2% | 13−37.1%27.1% | 21—26.9% | 0—0.0% | — | — | — | |
| Lease liabilities (non-current) | 1.5−14.4%2.5% | 1.7+18.6%2.9% | 1.4−44.5%2.7% | 2.6—5.5% | — | 1.8+2.2%2.3% | 1.8r1.8—4.0% | — | — | — | |
| Total liabilities | 20−24.3%35.3% | 27−13.8%45.0% | 31−5.1%59.2% | 33−29.3%69.8% | 46+5.6%94.8% | 44+81.6%56.1% | 24r24−5.1%54.1% | 25−2.3%48.1% | 26—44.0% | — | |
| Retained earnings | −403—−705% | −398—−672% | −397—−761% | −389—−834% | −370—−762% | −337—−434% | −307r−307—−692% | −272—−518% | −240—−409% | −214—−258% | |
| Shareholders' equity | 37+13.5%64.7% | 33+53.1%55.0% | 21+50.9%40.8% | 14+456%30.2% | 2.5−92.6%5.2% | 34+68.2%43.9% | 20r20−25.5%45.9% | 27r27−17.1%51.9% | 33−37.8%56.0% | 53—63.7% | |
| Total liabilities and equity | 57−3.5%100% | 59+13.5%100% | 52+11.9%100% | 47−4.0%100% | 49−37.5%100% | 78+75.4%100% | 44r44−15.7%100% | 53−10.6%100% | 59−29.3%100% | 83—100% | |
| Shares outstanding | 3.9r39−88.4%— | 34+16.9%— | 29+139%— | 12+42.4%— | 8.5r94−90.9%— | 94+43.1%— | 65+14.6%— | 57+10.2%— | 52+0.5%— | 52—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 2.2+0.6%3.2% | 2.2+51.0%2.1% | 1.4+151%1.7% | 0.6−13.8%0.8% | 0.7−19.9%1.1% | 0.8+5.8%1.3% | 0.8r0.8+21.2%1.3% | 0.7+26.4%1.0% | 0.5−32.5%0.9% | 0.8—1.4% | |
| Share-based compensation | 1.8+40.6%2.6% | 1.3+38.6%1.3% | 0.9+196%1.1% | 0.3−66.6%0.4% | 0.9+98.5%1.5% | 0.5−90.4%0.8% | 5.0r5.0+12.9%8.1% | 4.4−38.8%6.9% | 7.2r6.9−30.7%12.5% | 10—19.4% | |
| Cash from operating activities | −0.7−116%−1.0% | 4.2—4.1% | −9.4—−11.3% | −17r−17—−23.3% | −34—−54.1% | −30—−47.7% | −27r−27—−44.5% | −20—−32.2% | −21r−21—−36.8% | −12—−23.4% | |
| Capital expenditure | −0.5—−0.8% | −1.0—−1.0% | −0.3—−0.3% | — | — | — | — | — | — | — | |
| Cash from investing activities | −8.5—−12.3% | −4.9—−4.8% | −3.0—−3.6% | −2.4−870%−3.3% | 0.3−90.3%0.5% | 3.2—5.2% | −4.8r−4.7−137%−7.7% | 13−12.3%20.1% | 15—25.3% | −1.6—−3.1% | |
| Debt issued | — | — | — | — | 0−100%0.0% | 23—36.2% | 0—0.0% | — | — | — | |
| Debt repaid | — | 0—0.0% | −2.0—−2.4% | −12—−16.1% | −0.8—−1.2% | 0—0.0% | — | — | — | — | |
| Shares issued | 7.8−23.2%11.3% | 10−31.5%10.0% | 15−1.0%17.8% | 15—20.6% | — | — | 5.4−75.5%8.8% | 22+17699%34.7% | 0.1—0.2% | — | |
| Cash from financing activities | 4.3−42.1%6.1% | 7.3−35.2%7.2% | 11−29.8%13.6% | 16r17—22.2% | −2.2−103%−3.5% | 63+200%102% | 21r21−4.2%34.4% | 22—34.7% | −2.2−2799%−3.8% | 0.1—0.2% | |
| Exchange-rate effect on cash | 0—0.0% | −0.0—−0.0% | −0.0—−0.0% | −0.0—−0.0% | — | — | — | — | — | — | |
| Change in cash | −5.0−174%−7.1% | 6.7—6.6% | −1.1—−1.3% | −3.2—−4.4% | −35−196%−57.2% | 37—59.3% | −11r−11−176%−17.8% | 14—22.6% | −8.8—−15.3% | −14—−26.3% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 73−4.0%100% | 19+20.1%100% | 18+10.6%100% | 17−8.3%100% | 18*−25.6%100% | 16−43.8%100% | 16−37.8%100% | 19−16.6%100% | 25*+11.6%100% | 28—100% | 26—100% | 23—100% | 22*—100% | |
| Cost of revenue | 59−7.3%81.9% | 16+17.3%83.7% | 15+7.1%81.8% | 14−9.0%83.3% | 14*−31.2%78.9% | 14−38.1%85.7% | 14−36.2%84.4% | 16−19.1%83.9% | 21*+9.4%85.3% | 22—78.0% | 21—82.4% | 20—86.5% | 19*—87.0% | |
| Gross profit | 13+14.7%18.1% | 3.1+36.9%16.3% | 3.2+29.6%18.2% | 2.9−4.8%16.7% | 3.9*+6.8%21.1% | 2.3−63.6%14.3% | 2.5−45.0%15.6% | 3.0−0.7%16.1% | 3.6*+26.5%14.7% | 6.2—22.0% | 4.6—17.6% | 3.1—13.5% | 2.9*—13.0% | |
| Research and development | — | 0.1—0.6% | 0.0—0.2% | — | 0*−100%0.0% | 0—0.0% | 0—0.0% | 0−100%0.0% | 0.0*−99.4%0.0% | 0—0.0% | 0—0.0% | 0.0—0.1% | 0.2*—0.8% | |
| Selling and marketing | 2.3−15.1%3.1% | 0.6+7.7%3.0% | 0.6+0.9%3.2% | 0.6−20.3%3.3% | 0.5*−35.9%2.9% | 0.5−26.9%3.3% | 0.6−2.4%3.6% | 0.7+19.7%3.8% | 0.8*+55.8%3.4% | 0.7—2.6% | 0.6—2.3% | 0.6—2.6% | 0.5*—2.4% | |
| General and administrative | 15+10.5%20.7% | 3.8+14.3%19.9% | 3.7+12.4%20.7% | 3.8+3.2%22.0% | 3.7*+13.0%20.4% | 3.3−7.0%20.9% | 3.3−4.9%20.4% | 3.7−2.3%19.5% | 3.3*+22.1%13.4% | 3.6—12.6% | 3.4—13.4% | 3.8—16.7% | 2.7*—12.3% | |
| Operating income | −5.2—−7.1% | −2.2—−11.6% | −1.1—−6.0% | −1.5—−8.5% | −0.4*—−2.2% | −1.6−182%−9.9% | −1.3−362%−8.4% | −1.4—−7.2% | −0.5*—−2.1% | 1.9—6.8% | 0.5—2.0% | −1.3—−5.8% | −0.5*—−2.5% | |
| Interest expense and finance costs | 1.1+0.4%1.6% | 0.3−1.1%1.5% | 0.3+1.8%1.6% | 0.3+1.8%1.6% | 0.3*−1.0%1.6% | 0.3−5.6%1.8% | 0.3+19.0%1.7% | 0.3−35.7%1.5% | 0.3*−73.9%1.2% | 0.3—1.1% | 0.2—0.9% | 0.4—1.9% | 1.1*—5.0% | |
| Other non-operating income (expense) | −0.5—−0.7% | −0.1—−0.5% | −0.1—−0.6% | −0.1—−0.7% | −0.2*—−0.9% | −0.2—−1.1% | −0.1—−0.9% | −0.2—−0.8% | −0.2*—−1.0% | −0.3—−1.0% | −0.2—−0.7% | −0.4—−1.8% | −1.0*—−4.4% | |
| Net income attributable to shareholders | −5.7—−7.8% | −2.3—−12.2% | −1.2—−6.6% | −1.6—−9.3% | −0.6*—−3.0% | −1.8−205%−11.0% | −1.5−535%−9.3% | −1.5—−8.0% | −0.8*—−3.1% | 1.7—5.9% | 0.3—1.3% | −1.7—−7.6% | −1.5*—−6.8% | |
| Earnings per share, basic | — | -0.59—— | -0.34—— | -0.04—— | — | -0.49r-0.05−1080%— | -0.48r-0.05−4900%— | -0.04—— | — | 0.05—— | 0.01—— | -0.06—— | — | |
| Earnings per share, diluted | — | — | — | -0.04—— | — | -0.05−225%— | -0.05−600%— | -0.04—— | — | 0.04—— | 0.01—— | -0.06—— | — | |
| Shares, weighted average (basic) | 4.0+10.3%— | 4.0+10.3%— | 4.0+15.4%— | 39+15.6%— | — | 3.6r36−88.6%— | 3.4r34−88.7%— | 34+16.3%— | — | 32—— | 30—— | 29—— | — | |
| Shares, weighted average (diluted) | 4.0+10.3%— | 4.0+10.3%— | 4.0+15.4%— | 39+15.6%— | — | 3.6r36−88.9%— | 3.4r34−89.3%— | 34+16.3%— | — | 32—— | 32—— | 29—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 11—18.6% | 11−21.9%18.6% | 11−15.7%18.6% | 9.6−15.6%16.7% | 11−31.6%18.7% | 14+10.3%23.7% | 12+5.2%23.7% | 11+71.5%21.1% | 16+74.4%26.5% | 12—21.6% | 12—22.4% | 6.6—13.1% | 9.0—17.2% | |
| Short-term investments | — | — | — | — | 14+141%25.0% | — | — | — | 5.9+204%10.0% | 5.9—10.4% | 0—0.0% | 2.0—3.9% | 2.0—3.7% | |
| Receivables | 9.8—17.2% | 9.8+17.6%17.2% | 8.3+2.7%14.7% | 8.8−8.7%15.4% | 8.1−1.8%14.2% | 8.3−6.3%14.5% | 8.1−25.4%15.4% | 9.7−12.8%17.9% | 8.3−23.9%14.0% | 8.9—15.6% | 11—20.4% | 11—21.9% | 11—20.9% | |
| Inventory | 2.9—5.1% | 2.9−26.0%5.1% | 2.8−32.3%5.0% | 3.1−39.4%5.3% | 3.4−40.7%6.0% | 4.0−32.7%6.9% | 4.2−29.3%7.9% | 5.0−16.9%9.3% | 5.8−1.6%9.8% | 5.9—10.3% | 5.9—11.1% | 6.1—12.0% | 5.9—11.3% | |
| Other current assets | 1.9—3.3% | 1.9+25.5%3.3% | 0.4−53.2%0.8% | 1.2+18.7%2.0% | 1.6+17.7%2.8% | 1.5+29.4%2.6% | 0.9−19.2%1.8% | 1.0+8.6%1.8% | 1.4+27.8%2.3% | 1.2—2.1% | 1.2—2.2% | 0.9—1.8% | 1.1—2.0% | |
| Current assets | 37—65.1% | 37−0.9%65.1% | 36+15.0%64.3% | 37+11.8%64.3% | 38+3.1%66.8% | 38+9.6%65.3% | 32+6.2%60.1% | 33+23.7%61.2% | 37+28.7%62.5% | 34—59.9% | 30—56.1% | 27—52.6% | 29—55.1% | |
| Property, plant and equipment | 4.9—8.6% | 4.9−0.9%8.6% | 4.6−9.9%8.2% | 4.3−19.8%7.5% | 4.6−20.0%8.1% | 5.0−14.5%8.6% | 5.1−14.6%9.7% | 5.4−12.1%10.0% | 5.8−9.6%9.8% | 5.8—10.2% | 6.0—11.3% | 6.1—12.1% | 6.4—12.3% | |
| Right-of-use (leased) assets | 3.9—6.8% | 3.9+29.2%6.8% | 4.2+24.4%7.5% | 4.6+63.6%8.0% | 2.6−20.1%4.5% | 3.0−16.9%5.2% | 3.4−3.0%6.5% | 2.8−27.5%5.2% | 3.2+18.5%5.4% | 3.6—6.3% | 3.5—6.6% | 3.9—7.7% | 2.7—5.2% | |
| Goodwill | 0.9—1.6% | 0.90.0%1.6% | 0.9−0.1%1.6% | 0.90.0%1.6% | 0.90.0%1.6% | 0.90.0%1.6% | 0.90.0%1.8% | 0.90.0%1.7% | 0.90.0%1.6% | 0.9—1.6% | 0.9—1.7% | 0.9—1.8% | 0.9—1.8% | |
| Other intangible assets | 9.2—16.2% | 9.2−5.6%16.2% | 9.4−5.5%16.6% | 9.5−5.5%16.6% | 9.7−5.4%16.9% | 9.8−5.3%17.0% | 9.9−5.3%18.9% | 10−5.2%18.7% | 10−5.1%17.2% | 10—18.1% | 10—19.8% | 11—20.9% | 11—20.6% | |
| Total assets | 57—100% | 57−0.7%100% | 57+7.4%100% | 57+6.4%100% | 57−3.5%100% | 57+0.7%100% | 53−0.8%100% | 54+6.4%100% | 59+13.5%100% | 57—100% | 53—100% | 51—100% | 52—100% | |
| Accounts payable | 3.6—6.4% | 3.6+139%6.4% | 3.2+112%5.6% | 3.4+79.0%6.0% | 2.0−30.3%3.5% | 1.5−41.6%2.6% | 1.5−55.1%2.9% | 1.9−60.9%3.6% | 2.9−36.5%4.8% | 2.6—4.6% | 3.3—6.3% | 4.9—9.7% | 4.5—8.7% | |
| Debt due within a year | 2.8—5.0% | 2.8—5.0% | 1.8—3.1% | 0.7—1.2% | 0—0.0% | — | — | — | — | — | — | — | 0—0.0% | |
| Current liabilities | 15—26.4% | 15+57.3%26.4% | 11+2.1%19.8% | 9.9−11.9%17.2% | 9.6−32.0%16.8% | 9.6−32.4%16.7% | 11−26.5%20.8% | 11−25.0%20.8% | 14−15.3%23.8% | 14—24.8% | 15—28.1% | 15—29.5% | 17—31.9% | |
| Long-term debt | 6.2—10.9% | 6.2−28.8%10.9% | 7.2−16.3%12.8% | 8.2−4.1%14.3% | 8.8+4.2%15.4% | 8.7+4.2%15.2% | 8.6+4.3%16.4% | 8.6+3.6%15.9% | 8.5+2.2%14.3% | 8.4—14.7% | 8.3—15.6% | 8.3—16.3% | 8.3—15.9% | |
| Lease liabilities (non-current) | 2.6—4.6% | 2.6+53.2%4.6% | 2.9+46.1%5.2% | 3.3+136%5.7% | 1.5−14.4%2.5% | 1.7−17.8%3.0% | 2.0−6.3%3.8% | 1.4−44.0%2.6% | 1.7+18.6%2.9% | 2.1—3.7% | 2.1—4.0% | 2.5—4.9% | 1.4—2.7% | |
| Total liabilities | 24—42.0% | 24+17.0%42.0% | 21−3.5%37.9% | 22−3.9%37.6% | 20−24.3%35.3% | 20−26.8%35.6% | 22−24.8%42.2% | 22−25.4%41.6% | 27−13.8%45.0% | 28—49.0% | 30—55.7% | 30—59.3% | 31—59.2% | |
| Retained earnings | −408—−715% | −408—−715% | −406—−718% | −405—−705% | −403—−705% | −402—−700% | −401—−761% | −399—−740% | −398—−672% | −397—−695% | −399—−752% | −399—−786% | −397—−761% | |
| Shareholders' equity | 33—58.0% | 33−10.5%58.0% | 35+15.4%62.1% | 36+13.8%62.4% | 37+13.5%64.7% | 37r37+27.1%64.4% | 30+29.4%57.8% | 32+52.7%58.4% | 33+53.1%55.0% | 29—51.0% | 23—44.3% | 21—40.7% | 21—40.8% | |
| Total liabilities and equity | 57—100% | 57−0.7%100% | 57+7.4%100% | 57+6.4%100% | 57−3.5%100% | 57+0.7%100% | 53−0.8%100% | 54+6.4%100% | 59+13.5%100% | 57—100% | 53—100% | 51—100% | 52—100% | |
| Shares outstanding | 4.0—— | 4.0+0.8%— | 40r4.0+1054%— | 39+15.2%— | 3.9r39−88.4%— | 3.9r39−87.8%— | 3.4r34−88.9%— | 34+15.9%— | 34+16.9%— | 32—— | 31—— | 30—— | 29—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 2.1−4.1%2.9% | 0.6*+1.1%2.9% | 0.5*−12.6%2.8% | 0.5−5.2%2.9% | 0.5*+0.6%3.0% | 0.5*+0.2%3.4% | 0.6*+2.6%3.5% | 0.5−1.1%2.8% | 0.5*−1.3%2.2% | 0.5*—1.9% | 0.5*—2.1% | 0.5—2.4% | 0.6*—2.5% | |
| Share-based compensation | 1.7−0.6%2.4% | 0.4−26.5%2.0% | 0.4+5.5%2.3% | 0.5+7.6%2.8% | 0.5*+19.6%2.5% | 0.5+65.7%3.3% | 0.4+13.0%2.4% | 0.4+77.3%2.4% | 0.4*+75.2%1.5% | 0.3—1.1% | 0.3—1.3% | 0.3—1.1% | 0.2*—1.0% | |
| Cash from operating activities | 2.7—3.7% | −1.5*—−8.0% | 2.1*+12.8%11.7% | −0.2—−1.0% | 2.3*+165%12.5% | −1.3*−131%−8.2% | 1.8*+27.9%11.5% | −3.5—−18.4% | 0.9*—3.5% | 4.3*—15.1% | 1.4*—5.6% | −2.4—−10.5% | −0.0*—−0.2% | |
| Capital expenditure | −1.9—−2.5% | −0.7*—−3.8% | −0.6*—−3.5% | −0.4—−2.5% | −0.1*—−0.5% | −0.2*—−1.4% | −0.2*—−1.0% | −0.1—−0.3% | −0.4*—−1.6% | −0.2*—−0.7% | −0.3*—−1.1% | −0.1—−0.6% | −0.0*—−0.2% | |
| Cash from investing activities | −3.0—−4.1% | 1.8*—9.2% | −0.5*—−2.7% | −0.1—−0.7% | −4.1*—−22.5% | −4.3*—−27.1% | −0.1*−106%−0.6% | −0.0—−0.0% | −0.3*−117%−1.3% | −6.1*—−21.6% | 1.7*—6.6% | −0.1—−0.6% | 2.0*—9.1% | |
| Debt repaid | — | — | — | — | — | — | — | — | 0*—0.0% | — | — | — | −1.5*—−6.8% | |
| Shares issued | — | — | — | — | 0*−100%0.0% | 7.8*+115%49.1% | 0*−100%0.0% | 0−100%0.0% | 3.8*+245%15.4% | 3.6*—12.8% | 2.2*—8.5% | 0.6—2.5% | 1.1*—5.0% | |
| Cash from financing activities | −2.7−133%−3.7% | −0.1*−102%−0.6% | −0.7*—−3.8% | −0.8—−4.7% | −1.1*−138%−5.8% | 6.7*+192%42.3% | −0.7*−131%−4.0% | −0.8−540%−4.1% | 2.8*—11.3% | 2.3*—8.2% | 2.1*—8.0% | 0.2—0.8% | −0.7*—−3.4% | |
| Exchange-rate effect on cash | — | — | — | — | 0*—0.0% | 0*—0.0% | — | — | −0.0*−200%−0.0% | −0.0*—−0.0% | −0.0*—−0.0% | 0—0.0% | 0.0*—0.0% | |
| Change in cash | −3.0−334%−4.1% | 0.1*−90.1%0.6% | 0.9*−16.6%5.1% | −1.1—−6.4% | −2.9*−187%−15.8% | 1.1*+137%7.1% | 1.1*−79.1%6.8% | −4.3—−22.6% | 3.3*+172%13.5% | 0.5*—1.7% | 5.2*—20.2% | −2.3—−10.3% | 1.2*—5.5% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Rockwell Medical, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Concentrate Products Sales$69 M100%-32%
- License Fees$0 M0.5%+540%
Business segments
- Reportable$69 M100%-32%
Countries and regions
- 🇺🇸 USA$60 M87%-35%
- Rest of World(total)$9 M13%-3.6%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Executive pay at Rockwell Medical, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Mark Strobeck | $1.9 M | $1.1 M | $903 K | $82 |
| 2024Mark Strobeck | $1.3 M | $1.4 M | $645 K | $202 |
| 2023Mark Strobeck | $1.1 M | $1.8 M | $427 K | $187 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Rockwell Medical, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Delisting noticeFiling
Delisting notice 1 · Directors and officers 3 · Material agreement 1 · Unregistered share sale 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 10
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Shareholder vote | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
FDA drug approvals: Rockwell Medical, Inc.#
3 approved applications held; 1 approvals and 0 new uses in 2020.
| Approved | Drug | Kind |
|---|---|---|
| 2020-03-27 | Triferic AvnuFerric Pyrophosphate Citrate · NDA212860 | New drug (NDA) |
| 2016-04-25 | TrifericFerric Pyrophosphate Citrate · NDA208551 | New drug (NDA) |
| 2015-01-23 | TrifericFerric Pyrophosphate Citrate · NDA206317 | New drug (NDA) |
Source: Drugs@FDA (openFDA). Approvals are listed under the application's current holder (ROCKWELL MEDICAL INC), so they follow acquisitions
Product recalls by Rockwell Medical, Inc.#
1 recalls since 2015, 139 units in the notices that give a number. Medical devices (FDA): 1.
| Date | What and why | Units | Notice |
|---|---|---|---|
| DriSate¿ Product Code DR-145 The acid concentrate powders and liquids are indicated for use in acute and chronic hemodialysis and to be used with the appropriate hemodialysis machine/monitor and bicarbonate concentrate.A subassembly component (dextrose bag) within this case product contained small amounts of sodium bicarbonate from a prior batch.Medical devicesClass II | 139 | Z-1869-2018 |
Source: NHTSA, CPSC and FDA recall notices. Recalls filed under a subsidiary with a different name may be missing. The number of recalls says nothing about their seriousness
How Rockwell Medical, Inc. compares in Pharmaceutical
- Market cap$32 M · higher than 10% of 393
- Revenue$69 M · higher than 18% of 324
- Net margin-7.8% · higher than 20% of 313
- Revenue growth-31.8% · higher than 6% of 107
- Price / sales0.4× · lower than 94% of 219
- Price / book0.9× · lower than 85% of 207
- FCF yield-3.7% · higher than 26% of 69
Peer comparison · Pharmaceutical
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Rockwell Medical, Inc.🇺🇸 | $32 M | — | -7.8% | -31.8% |
| Eli Lilly and Company🇺🇸 | $1.20 T | 43.4× | 31.9% | +44.7% |
| Johnson & Johnson🇺🇸 | $652.5 B | 40.5× | 16.2% | +6.0% |
| AbbVie Inc.🇺🇸 | $514.0 B | 49.7× | 15.7% | +8.6% |
| Roche Holding AG🇨🇭 | $370.3 B | 29.1× | 19.0% | — |
| Merck & Co., Inc.🇺🇸 | $359.8 B | 146.7× | 3.6% | +1.3% |
| Novartis AG🇨🇭 | $286.8 B | 20.5× | 24.7% | — |
| Amgen Inc.🇺🇸 | $249.2 B | 26.5× | 24.1% | +9.9% |
| AstraZeneca PLC🇬🇧 | $242.6 B | 23.7× | 17.4% | +8.6% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Korea United Pharm Inc.$191 M
- Suheung Co., Ltd.$199 M
- JW Holdings Corporation$206 M
- Hester Biosciences Limited$214 M
- Venus Remedies Limited$215 M
- Windlas Biotech Limited$217 M
Sources and freshness
- Market cap:
- Oct 16, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, Wikipedia, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Rockwell Medical, Inc.? Verify and update this profile — free
Show Rockwell Medical, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.